Schedule of Changes In Consolidated Equity |
The following tables present the changes in consolidated equity (dollars in millions, share amounts in thousands): | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Common Stock | | Additional Paid-In Capital | | Accumulated Other Comprehensive Loss | | Retained Earnings | | Treasury Stock | | Noncontrolling Interests | | Total Equity | | | | | | | Shares Outstanding | | Issued Par Amount | | | | | | | | | | | Balances at December 31, 2024 | | 95,109 | | | $ | 8 | | | $ | 4,873 | | | $ | (180) | | | $ | 3,008 | | | $ | (3,538) | | | $ | 1,649 | | | $ | 5,820 | | | | | | Net income | | — | | | — | | | — | | | — | | | 406 | | | — | | | 95 | | | 501 | | | | | | Distributions paid to noncontrolling interests | | — | | | — | | | — | | | — | | | — | | | — | | | (89) | | | (89) | | | | | | Other comprehensive income | | — | | | — | | | — | | | 2 | | | — | | | — | | | — | | | 2 | | | | | | | | | | | | | | | | | | | | | | | | | | | Net purchases (sales) of businesses and noncontrolling interests | | — | | | — | | | (35) | | | — | | | — | | | — | | | 41 | | | 6 | | | | | | | | | | | | | | | | | | | | | | | | | | | Repurchases of common stock | | (2,629) | | | — | | | — | | | — | | | — | | | (351) | | | — | | | (351) | | | | | | Stock-based compensation expense, tax benefit and issuance of common stock | | 405 | | | — | | | (12) | | | — | | | — | | | — | | | — | | | (12) | | | | | | Balances at March 31, 2025 | | 92,885 | | | 8 | | | 4,826 | | | (178) | | | 3,414 | | | (3,889) | | | 1,696 | | | 5,877 | | | | | | Net income | | — | | | — | | | — | | | — | | | 288 | | | — | | | 105 | | | 393 | | | | | | Distributions paid to noncontrolling interests | | — | | | — | | | — | | | — | | | — | | | — | | | (83) | | | (83) | | | | | | Other comprehensive income | | — | | | — | | | — | | | 1 | | | — | | | — | | | — | | | 1 | | | | | | | | | | | | | | | | | | | | | | | | | | | Net purchases of businesses and noncontrolling interests | | — | | | — | | | 10 | | | — | | | — | | | — | | | 9 | | | 19 | | | | | | Repurchases of common stock | | (4,601) | | | — | | | — | | | — | | | — | | | (753) | | | — | | | (753) | | | | | | | | | | | | | | | | | | | | | | | | | | | Stock-based compensation expense, tax benefit and issuance of common stock | | 60 | | | — | | | 22 | | | — | | | — | | | — | | | — | | | 22 | | | | | | Balances at June 30, 2025 | | 88,344 | | | $ | 8 | | | $ | 4,858 | | | $ | (177) | | | $ | 3,702 | | | $ | (4,642) | | | $ | 1,727 | | | $ | 5,476 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Common Stock | | Additional Paid-In Capital | | Accumulated Other Comprehensive Loss | | Retained Earnings (Accumulated Deficit) | | Treasury Stock | | Noncontrolling Interests | | Total Equity | | | Shares Outstanding | | Issued Par Amount | | | | | | | Balances at December 31, 2023 | | 99,950 | | | $ | 8 | | | $ | 4,834 | | | $ | (181) | | | $ | (192) | | | $ | (2,861) | | | $ | 1,509 | | | $ | 3,117 | | Net income | | — | | | — | | | — | | | — | | | 2,151 | | | — | | | 82 | | | 2,233 | | Distributions paid to noncontrolling interests | | — | | | — | | | — | | | — | | | — | | | — | | | (78) | | | (78) | | Other comprehensive income | | — | | | — | | | — | | | 2 | | | — | | | — | | | — | | | 2 | | | | | | | | | | | | | | | | | | | Net sales of businesses and noncontrolling interests | | — | | | — | | | (5) | | | — | | | — | | | — | | | (23) | | | (28) | | Repurchases of common stock | | (2,811) | | | — | | | — | | | — | | | — | | | (280) | | | — | | | (280) | | | | | | | | | | | | | | | | | | | Stock-based compensation expense, tax benefit and issuance of common stock | | 534 | | | — | | | (23) | | | — | | | — | | | — | | | — | | | (23) | | Balances at March 31, 2024 | | 97,673 | | | 8 | | | 4,806 | | | (179) | | | 1,959 | | | (3,141) | | | 1,490 | | | 4,943 | | Net income | | — | | | — | | | — | | | — | | | 259 | | | — | | | 97 | | | 356 | | Distributions paid to noncontrolling interests | | — | | | — | | | — | | | — | | | — | | | — | | | (70) | | | (70) | | Other comprehensive income | | — | | | — | | | — | | | 2 | | | — | | | — | | | — | | | 2 | | | | | | | | | | | | | | | | | | | Net purchases of businesses and noncontrolling interests | | — | | | — | | | 12 | | | — | | | — | | | — | | | 64 | | | 76 | | Repurchases of common stock | | (1,990) | | | — | | | — | | | — | | | — | | | (273) | | | — | | | (273) | | | | | | | | | | | | | | | | | | | Stock-based compensation expense and issuance of common stock | | 136 | | | — | | | 22 | | | — | | | — | | | — | | | — | | | 22 | | Balances at June 30, 2024 | | 95,819 | | | $ | 8 | | | $ | 4,840 | | | $ | (177) | | | $ | 2,218 | | | $ | (3,414) | | | $ | 1,581 | | | $ | 5,056 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
|
Schedule of Changes in Redeemable Noncontrolling Interests in Equity of Consolidated Subsidiaries |
The table below presents our nonredeemable noncontrolling interests balances by segment: | | | | | | | | | | | | | | | | | June 30, 2025 | | December 31, 2024 | Hospital Operations | | $ | 215 | | | $ | 205 | | Ambulatory Care | | 1,512 | | | 1,444 | | Total nonredeemable noncontrolling interests | | $ | 1,727 | | | $ | 1,649 | |
The table below presents our income available to nonredeemable noncontrolling interests by segment: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Three Months Ended June 30, | | Six Months Ended June 30, | | | 2025 | | 2024 | | 2025 | | 2024 | Hospital Operations | | $ | 12 | | | $ | 12 | | | $ | 24 | | | $ | 21 | | Ambulatory Care | | 93 | | | 85 | | | 176 | | | 158 | | Total net income available to nonredeemable noncontrolling interests | | $ | 105 | | | $ | 97 | | | $ | 200 | | | $ | 179 | |
|
Schedule of Share Repurchase Activity |
The table below presents repurchase activity under both the 2022 and 2024 share repurchase programs: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Period | | | | Total Number of Shares Purchased | | Average Price Paid per Share | | Total Number of Shares Purchased as Part of Publicly Announced Program | | Maximum Dollar Value of Shares That May Yet Be Purchased Under the Program(1) | | | | | (In Thousands) | | | | (In Thousands) | | (In Millions) | Six Months Ended June 30, 2025: | | | | | | | | | | | January 1 through January 31, 2025 | | | | — | | $ | — | | | — | | $ | 1,376 | | February 1 through February 28, 2025 | | | | 1,800 | | $ | 134.98 | | | 1,800 | | $ | 1,133 | | March 1 through March 31, 2025 | | | | 829 | | $ | 126.67 | | | 829 | | $ | 1,028 | | April 1 through April 30, 2025 | | | | — | | $ | — | | | — | | $ | 1,028 | | May 1 through May 31, 2025 | | | | 2,456 | | $ | 157.57 | | | 2,456 | | $ | 641 | | June 1 through June 30, 2025 | | | | 2,145 | | $ | 167.83 | | | 2,145 | | $ | 281 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | January 1 through June 30, 2025 | | | | 7,230 | | $ | 151.45 | | | 7,230 | | | | | | | | | | | | | | Six Months Ended June 30, 2024: | | | | | | | | | | | January 1 through January 31, 2024 | | | | — | | $ | — | | | — | | $ | 550 | | February 1 through February 29, 2024 | | | | — | | $ | — | | | — | | $ | 550 | | March 1 through March 31, 2024 | | | | 2,811 | | $ | 98.86 | | | 2,811 | | $ | 272 | | April 1 through April 30, 2024 | | | | — | | $ | — | | | — | | $ | 272 | | May 1 through May 31, 2024 | | | | — | | $ | — | | | — | | $ | 272 | | June 1 through June 30, 2024 | | | | 1,990 | | $ | 135.85 | | | 1,990 | | $ | 2 | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | January 1 through June 30, 2024 | | | | 4,801 | | $ | 114.19 | | | 4,801 | | |
| | | | | | | | | | | | (1) | In July 2025, our board of directors authorized a $1.500 billion increase to the 2024 share repurchase program. With this new authorization, $1.781 billion was available for repurchases of our common stock as of July 22, 2025. | | | | |
|